DE69929440D1 - Zusammensetzungen zur behandlung chronischer lymphatischer leukämie - Google Patents

Zusammensetzungen zur behandlung chronischer lymphatischer leukämie

Info

Publication number
DE69929440D1
DE69929440D1 DE69929440T DE69929440T DE69929440D1 DE 69929440 D1 DE69929440 D1 DE 69929440D1 DE 69929440 T DE69929440 T DE 69929440T DE 69929440 T DE69929440 T DE 69929440T DE 69929440 D1 DE69929440 D1 DE 69929440D1
Authority
DE
Germany
Prior art keywords
compositions
treatment
lymphatic leukemia
chronic lymphatic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69929440T
Other languages
English (en)
Other versions
DE69929440T2 (de
Inventor
Francis A Nardella
Ruth L Sitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Salmedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salmedix Inc filed Critical Salmedix Inc
Application granted granted Critical
Publication of DE69929440D1 publication Critical patent/DE69929440D1/de
Publication of DE69929440T2 publication Critical patent/DE69929440T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69929440T 1998-07-09 1999-07-08 Zusammensetzungen zur behandlung chronischer lymphatischer leukämie Expired - Fee Related DE69929440T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9246698P 1998-07-09 1998-07-09
US92466P 1998-07-09
US9487898P 1998-07-29 1998-07-29
US94878P 1998-07-29
PCT/US1999/015501 WO2000002555A1 (en) 1998-07-09 1999-07-08 Methods and compositions for the treatment of chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
DE69929440D1 true DE69929440D1 (de) 2006-04-06
DE69929440T2 DE69929440T2 (de) 2006-08-17

Family

ID=26785713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929440T Expired - Fee Related DE69929440T2 (de) 1998-07-09 1999-07-08 Zusammensetzungen zur behandlung chronischer lymphatischer leukämie

Country Status (12)

Country Link
US (3) US6573292B1 (de)
EP (1) EP1104297B8 (de)
JP (1) JP2002520282A (de)
AT (1) ATE315392T1 (de)
AU (1) AU767586B2 (de)
CA (1) CA2336932A1 (de)
DE (1) DE69929440T2 (de)
DK (1) DK1104297T3 (de)
ES (1) ES2255287T3 (de)
NZ (1) NZ509376A (de)
PT (1) PT1104297E (de)
WO (1) WO2000002555A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
WO2004026116A2 (en) 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
WO2005033112A2 (en) * 2003-10-02 2005-04-14 Cephalon, Inc. Substituted indole derivatives
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
EP1814544A4 (de) * 2004-11-05 2009-12-02 Cephalon Inc Krebsbehandlungen
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EA021331B1 (ru) * 2008-05-20 2015-05-29 Общество С Ограниченной Ответственностью "Инкурон" Индуцирование клеточной гибели путем ингибирования адаптивной реакции теплового шока
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
MX2011007557A (es) * 2009-01-15 2011-08-12 Cephalon Inc Formas nuevas de bendamustina como base libre.
KR20140022750A (ko) 2010-08-18 2014-02-25 델 마 파마슈티컬스 인코포레이티드 디안하이드로갈락티톨 및 디아세틸디안하이드로갈락티톨과 같은 치환된 헥시톨을 포함하는 준최적하게 투여되는 화학적 화합물의 치료상 이점을 향상시키기 위한 조성물 및 방법
EP3795145A3 (de) 2011-08-17 2021-06-09 Dennis M. Brown Zusammensetzungen und verfahren zur erhöhung des therapeutischen nutzens von suboptimal verabreichten chemischen verbindungen einschliesslich substituierter hexitole wie dibromodulcitol
BR112014017833A2 (pt) 2012-01-20 2021-03-23 Dennis Brown Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma
EP2827869A4 (de) 2012-03-23 2015-09-23 Dennis Brown Zusammensetzungen und verfahren zur verbesserung des therapeutischen nutzens von indirubin und analoga davon, mit meisoindigo
WO2013169600A1 (en) 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
EP2872161B1 (de) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol zur verwendung bei der behandlung von tyrosinkinaseinhibitor-resistenten malignomen bei patienten mit genetischen polymorphismen oder ahi1-dysregulierungen oder mutationen
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
EP3129022A4 (de) 2014-04-06 2018-02-21 Incuron, Llc Kombinationstherapie mit curaxinen
JP7054691B2 (ja) 2016-05-04 2022-04-14 インメド ファーマシューティカルズ インコーポレイティド 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1071897B (de) 1957-12-19 1959-12-24
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3839178A (en) * 1972-10-05 1974-10-01 Gen Electric Potentiometric oxygen sensor
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4686213A (en) 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
CA2131992A1 (en) 1992-03-13 1993-09-16 James W. Young Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
MX9800568A (es) * 1995-07-19 1998-04-30 Merck & Co Inc Uso de agentes anti-inflamatorios no esteroidales.
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
WO1997048391A2 (en) 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
AU4043397A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Pyranoindole and carbazole inhibitors of cox-2
ATE305301T1 (de) * 1996-11-05 2005-10-15 Childrens Medical Center Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
CA2419060A1 (en) 2000-08-09 2002-02-14 The Regents Of The University Of California Indole compounds useful for the treatment of cancer

Also Published As

Publication number Publication date
NZ509376A (en) 2003-10-31
AU5209899A (en) 2000-02-01
ES2255287T3 (es) 2006-06-16
ATE315392T1 (de) 2006-02-15
DE69929440T2 (de) 2006-08-17
DK1104297T3 (da) 2006-05-29
EP1104297B1 (de) 2006-01-11
EP1104297A1 (de) 2001-06-06
EP1104297B8 (de) 2006-05-03
US6573292B1 (en) 2003-06-03
EP1104297A4 (de) 2003-01-02
US20050261356A1 (en) 2005-11-24
PT1104297E (pt) 2006-05-31
AU767586B2 (en) 2003-11-20
JP2002520282A (ja) 2002-07-09
US20030232874A1 (en) 2003-12-18
US6921772B2 (en) 2005-07-26
WO2000002555A1 (en) 2000-01-20
CA2336932A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
DE69929440D1 (de) Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
DE60034689D1 (de) Phytochemikalien zur behandlung von mastalgie und endometriose
SE9103752D0 (sv) New compounds
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
NZ506329A (en) Inhibitors of phospholipase enzymes
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
ATE401076T1 (de) Chinolinderivate als glucokinase liganden
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
RS20050041A (en) Azaindole kinase inhibitors
TR199901411T2 (xx) Analjezik etkili yeni bile�imler.
BR0011130A (pt) Inibidores de metaloproteases
CA2330756A1 (en) Indole derivatives and their use for the treatment of malignant and other diseases based on pathological cell proliferation
DE69719755D1 (de) Polymorphe verbindungen
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
MY136767A (en) Formulations comprising an indolinone compound
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
DK0971922T3 (da) Tetrahydropyrido-forbindelser
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
EP1671631A3 (de) Zusammensetzungen zur Behandlung von chronischer lymphatischer Leukämie
ATE306483T1 (de) Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
YU29496A (sh) So pirolidinil metil indola

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CEPHALON, INC., FRAZER, PA., US

8381 Inventor (new situation)

Inventor name: NARDELLA, FRANCIS A., SCOTTSDALE, ARIZ., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee